• Harrow acquires Tyrvaya varenicline nasal spray for the treatment of dry eye disease

  US-based opthalmic pharmaceuticals company Harrow announced that it will pay Viatris $30 million up front and up to $70 million in milestone payments to acquire Tyrvaya varenicline nasal spray. Tyrvaya was approved by the FDA… [Read more . . .]

• Savara gets 2 new patents covering Molbreevi molgramostim inhalation solution

  Savara has announced that the European Patent Office and the Australian Patent Office have issued new patents covering Molbreevi molgramostim inhalation solution. Both the European patent, No.4121000, and the Australian patent, No. 62/990,810, protect Molbreevi… [Read more . . .]

• MannKind says that the Phase 1b INFLO-1 trial of its nintedanib DPI met its primary endpoint

  MannKind Corporation announced that the Phase 1b INFLO-1 safety and tolerability trial of its nintedanib dry powder inhaler met its primary endpoint, demonstrating safety and tolerability. The multiple ascending dose study enrolled 27 patients with… [Read more . . .]

• Nasus Pharma names Brendan O’Grady as its new CEO

  Intranasal drug developer Nasus Pharma announced that it has hired former Teva USA President and CEO Brendan O’Grady as its new CEO. O’Grady was most recently CEO of Assertio Holdings and was previously CEO of… [Read more . . .]

• Chiesi returns the rights to seralutinib DPI for pulmonary hypertension to Gossamer

  Gossamer Bio announced that it has reacquired the ex-US rights to its seralutinib dry powder inhaler for the treatment of pulmonary hypertension from Chiesi, which acquired the rights to the seralutinib DPI in 2024. According to… [Read more . . .]

• Revagenix initiates Phase 1 trial of Rev-56 inhaled antibiotic for NCFB

• FDA approves Cipla’s ANDA for a generic of Advair Diskus fluticasone / salmeterol DPI

• CHMP adopts negative opinion regarding Cessatech and Proveca’s KemSu (CT001) sufentanil / ketamine nasal spray for pediatric patients

• Nanopharm facility in Wales gets GMP certification

• HFO 1234ze formulation of AstraZeneca’s Breztri Aerosphere budesonide / glycopyrronium / formoterol MDI approved in Australia

More news . . .